Human papillomavirus vaccines six years after approval

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 91-100

  Shaw, Alan R ^a  

^a Vedantra Pharmaceuticals   (United States)

Author keywords

cervical cancer; genital warts; Pap smears

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; FOLLOW UP; IMMUNITY; IMMUNIZATION; PRIORITY JOURNAL; SEXUAL BEHAVIOR; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

DRUG APPROVAL; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RETROSPECTIVE STUDIES;

EID: 84873019538     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-061511-125226     Document Type: Article

References (45)

1. Shaw A. 2004. Human papillomavirus vaccines and prevention of cervical cancer. Annu. Rev. Med. 55:319-31
2. Koutsky LA, Ault KA, Wheeler CM, et al. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-51
3. Billich A. 2003. HPV vaccine MedImmune/GlaxoSmithKline. Curr. Opin. Invest. Drugs 4:210-13
4. Ault KA. 2007. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861-68
5. Paavonen J, Naud P, Salmeron J, et al. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine against cervical infection and precancer caused by oncogenicHPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-14
6. Haupt RM, Wheeler CM, Brown DR, et al. 2011. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int. J. Cancer 129:2632-42
7. Moreira ED Jr, Palefsky JM, Giuliano AR, et al. 2011. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Hum. Vaccines 7:768-75
8. Reisinger KS, Block SL, Lazcano-Ponce E, et al. 2007. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr. Infect. Dis. J. 26:201-9
9. Einstein MH, Baron M, Levin MJ, et al. 2009. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccines 5:705-19
10. Future II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356:1915-27
11. Garland SM, Hernandez-Avila M, Wheeler CM, et al. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356:1928-43
12. Joura EA, Leodolter S, Hernandez-Avila M, et al. 2007. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369:1693-702
13. Munoz N, Kjaer SK, Sigurdsson K, et al. 2010. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl. Cancer Inst. 102:325-39
14. Olsson SE, Villa LL, Costa RL, et al. 2007. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25:4931-39
15. Einstein MH, Baron M, Levin MJ, et al. 2011. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum. Vaccines 7:1343-58
16. Wheeler CM, Castellsague X, Garland SM, et al. 2012. Cross-protective efficacy of HPV-16/18 AS04- adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13:100-10
17. Smith JF, Brownlow M, Brown M, et al. 2007. Antibodies from women immunized with Gardasil crossneutralize HPV 45 pseudovirions. Hum. Vaccines 3:109-15
18. BrownDR, Kjaer SK, Sigurdsson K, et al. 2009. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199:926-35
19. Wheeler CM, Kjaer SK, Sigurdsson K, et al. 2009. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J. Infect. Dis. 199:936-44
20. Opalka D, Matys K, Bojczuk P, et al. 2010. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin. Vaccine Immunol. 17:818-27
21. Zimet GD, Stupiansky NW, Weiss TW, et al. 2011. Influence of patient's relationship status and HPV history on physicians' decisions to recommend HPV vaccination. Vaccine 29:378-81
22. Zimet GD, Weiss TW, Rosenthal SL, et al. 2010. Reasons for non-vaccination against HPV and future vaccination intentions among 19-26 year-old women. BMC Women's Health 10:27
23. Chao C, Velicer C, Slezak JM, et al. 2009. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin. Proc. 84:864-70
24. Reisinger KS, Block SL, Collins-Ogle M, et al. 2010. Safety, tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel. Pediatrics 125:1142-51
25. Vesikari T, Van Damme P, Lindblad N, et al. 2010. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr. Infect. Dis. J. 29:314-18
26. Petaja T, KeranenH, Karppa T, et al. 2009. Immunogenicity and safety of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J. Adolesc. Health: Off. Publ. Soc. Adolesc. Med. 44:33-40
27. Palefsky JM, Giuliano AR, Goldstone S, et al. 2011. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 365:1576-85
28. Guimaraes MD, Grinsztejn B, Melo VH, et al. 2011. Anal HPV prevalence and associated factors among HIV-seropositive men under antiretroviral treatment in Brazil. J. Acquir. Immune Defic. Syndr. 57(Suppl. 3):S217-24
29. Elbasha EH, Dasbach EJ. 2010. Impact of vaccinating boys and men against HPV in the United States. Vaccine 28:6858-67
30. Grant LA, Dunne EF, Chesson H, et al. 2011. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States. Vaccine 29:2365-70
31. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. 2009. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 373:1949-57
32. Schwarz TF, Spaczynski M, Schneider A, et al. 2009. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 27:581-87
33. Perez G, Lazcano-Ponce E, Hernandez-Avila M, et al. 2008. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int. J. Cancer 122:1311-18
34. Kang S, Kim KH, Kim YT, et al. 2008. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. Int. J. Gynecol. Cancer 18:1013-19
35. Newall AT, Brotherton JM, Quinn HE, et al. 2008. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin. Infect. Dis. 46:1647 -55
36. Paavonen J. 2008. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. Curr. Med. Res. Opin. 24:1623-34
37. Six L, Leodolter S, Sings HL, et al. 2008. Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women-baseline data of a phase III vaccine trial. Wiener Klin. Wochenschr. 120:666-71
38. Skjeldestad FE, Mehta V, Sings HL, et al. 2008. Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstet. Gynecol. Scand. 87:81-88
39. Furniss CS, McCleanMD, Smith JF, et al. 2007. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int. J. Cancer 120:2386-92
40. Settle K, PosnerMR, Schumaker LM, et al. 2009. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev. Res. 2:776-81
41. Dasbach EJ, Insinga RP, Yang YC, et al. 2008. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pac. J. Cancer Prev. 9:459-66
42. Insinga RP, Dasbach EJ, Elbasha EH. 2008. Structural differences among cost-effectiveness models of human papillomavirus vaccines. Expert Rev. Vaccines 7:895-913
43. Insinga RP, Dasbach EJ, Allen SE, et al. 2008. Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation. Value Health 11:1022-32
44. Bonanni P, Cohet C, Kjaer SK, et al. 2010. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine 28:4719-30
45. Markowitz LE, Hariri S, Unger ER, et al. 2010. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 28:4731-37